Last edition
News about "HETRONIFLY"
Intas Pharmaceuticals has launched HETRONIFLY (Serplulimab), the world’s first PD-1 inhibitor approved for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in the Indian market.
HETRONIFLY | 06/08/2025 | By Mrinmoy Dey | 131
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members